US20220119819A1 - Formulation - Google Patents
Formulation Download PDFInfo
- Publication number
- US20220119819A1 US20220119819A1 US17/570,051 US202217570051A US2022119819A1 US 20220119819 A1 US20220119819 A1 US 20220119819A1 US 202217570051 A US202217570051 A US 202217570051A US 2022119819 A1 US2022119819 A1 US 2022119819A1
- Authority
- US
- United States
- Prior art keywords
- composition
- seq
- eye
- sodium
- inflammation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 238000009472 formulation Methods 0.000 title abstract description 13
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 43
- 206010013774 Dry eye Diseases 0.000 claims description 41
- 238000011282 treatment Methods 0.000 claims description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 208000006673 asthma Diseases 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 18
- 230000004054 inflammatory process Effects 0.000 claims description 18
- 206010061218 Inflammation Diseases 0.000 claims description 17
- 241000792859 Enema Species 0.000 claims description 12
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 12
- 239000007920 enema Substances 0.000 claims description 12
- 229940095399 enema Drugs 0.000 claims description 12
- 208000024908 graft versus host disease Diseases 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 201000009890 sinusitis Diseases 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 8
- 208000002389 Pouchitis Diseases 0.000 claims description 8
- 230000005855 radiation Effects 0.000 claims description 7
- 206010039083 rhinitis Diseases 0.000 claims description 7
- 206010036774 Proctitis Diseases 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 150000001768 cations Chemical class 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 4
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 4
- 229960003476 methylparaben sodium Drugs 0.000 claims description 4
- 229960005359 propylparaben sodium Drugs 0.000 claims description 4
- PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical compound [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 claims description 4
- IXMINYBUNCWGER-UHFFFAOYSA-M sodium;4-propoxycarbonylphenolate Chemical compound [Na+].CCCOC(=O)C1=CC=C([O-])C=C1 IXMINYBUNCWGER-UHFFFAOYSA-M 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000010408 film Substances 0.000 claims description 2
- 229940045641 monobasic sodium phosphate Drugs 0.000 claims description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 2
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 2
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 abstract description 15
- 241001465754 Metazoa Species 0.000 description 37
- 108010058846 Ovalbumin Proteins 0.000 description 28
- ZMJWRJKGPUDEOX-LMXUULCNSA-A alicaforsen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)[C@@H](OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([S-])(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)C1 ZMJWRJKGPUDEOX-LMXUULCNSA-A 0.000 description 28
- 229950011466 alicaforsen Drugs 0.000 description 28
- 229940092253 ovalbumin Drugs 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- 239000003981 vehicle Substances 0.000 description 21
- 108020004414 DNA Proteins 0.000 description 15
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 230000004941 influx Effects 0.000 description 12
- 230000004913 activation Effects 0.000 description 11
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 9
- 239000005557 antagonist Substances 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 9
- 229960003957 dexamethasone Drugs 0.000 description 9
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 9
- 210000004969 inflammatory cell Anatomy 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- KDWFDOFTPHDNJL-TUBOTVQJSA-N odn-2006 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(S)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)[C@@H](O)C1 KDWFDOFTPHDNJL-TUBOTVQJSA-N 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 8
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 8
- 108090000176 Interleukin-13 Proteins 0.000 description 8
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 8
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 210000004877 mucosa Anatomy 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 8
- 229960002646 scopolamine Drugs 0.000 description 8
- 102000002689 Toll-like receptor Human genes 0.000 description 7
- 108020000411 Toll-like receptor Proteins 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 238000010172 mouse model Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 229940063675 spermine Drugs 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 6
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 210000003979 eosinophil Anatomy 0.000 description 6
- 230000000069 prophylactic effect Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000004489 tear production Effects 0.000 description 6
- 206010009900 Colitis ulcerative Diseases 0.000 description 5
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 5
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 5
- 206010028116 Mucosal inflammation Diseases 0.000 description 5
- 206010070834 Sensitisation Diseases 0.000 description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 description 5
- 201000009961 allergic asthma Diseases 0.000 description 5
- 229940037003 alum Drugs 0.000 description 5
- 238000002983 circular dichroism Methods 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 210000005007 innate immune system Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 239000001509 sodium citrate Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 description 5
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001142 circular dichroism spectrum Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000002327 eosinophilic effect Effects 0.000 description 4
- 210000003714 granulocyte Anatomy 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229940042717 optimmune Drugs 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108010057466 NF-kappa B Proteins 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000015788 innate immune response Effects 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 210000004561 lacrimal apparatus Anatomy 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000002850 nasal mucosa Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 108091035539 telomere Proteins 0.000 description 3
- 102000055501 telomere Human genes 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 238000011814 C57BL/6N mouse Methods 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000036428 airway hyperreactivity Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000036449 good health Effects 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 206010051559 Corneal defect Diseases 0.000 description 1
- 108091029430 CpG site Proteins 0.000 description 1
- 206010051392 Diapedesis Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 206010015967 Eye swelling Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100481579 Mus musculus Tlr11 gene Proteins 0.000 description 1
- 101100481580 Mus musculus Tlr12 gene Proteins 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 description 1
- 108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 description 1
- 238000012338 Therapeutic targeting Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- WYEMLYFITZORAB-UHFFFAOYSA-N boscalid Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1NC(=O)C1=CC=CN=C1Cl WYEMLYFITZORAB-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000012321 colectomy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 231100000269 corneal opacity Toxicity 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000001526 defensive cell Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 201000004356 excessive tearing Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000005206 flow analysis Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 102000043559 human ICAM1 Human genes 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000021401 pellet diet Nutrition 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000036544 posture Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- LACQPOBCQQPVIT-SEYKEWMNSA-N scopolamine hydrobromide trihydrate Chemical compound O.O.O.Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 LACQPOBCQQPVIT-SEYKEWMNSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
Definitions
- the present invention relates to a new formulation of the oligonucleotide of SEQ ID NO: 1.
- Mucosal surfaces represent the first interface between the internal environment of the host organism and the external environment. Mucosal surfaces are therefore enriched in a variety of cellular and acellular structures that protect the host from foreign pathogen or antigen exposure. These important surfaces are represented by the mucosal surfaces of the oral and nasal (sinus) cavity, the pulmonary and digestive systems and mucosal tissues surrounding the eye.
- the cells comprising the mucosa are equipped to sense and respond to a variety of foreign substances. These cells also elaborate a variety of molecular pathways to communicate such invasion to the surrounding tissues and recruit an influx of additional inflammatory and immune cells to fight the infection, repair damage and if necessary induce specific immune responses in the form of antibodies. While these mechanisms serve an important and indeed life-saving function for the organism, their chronic and/or misguided activation can lead to considerable morbidity and mortality.
- the chronic influx of inflammatory cells and the subsequent local activation of cells of the immune system are two primary loci where chronic mucosal inflammation can be controlled. These responses are part of the “innate immune system”.
- the first responding cells of the innate immune system such as dendritic cells and macrophages, ingest pathogens and release cytokines drawing secondary, active and defensive cells from the blood. These secondary invading cells must be “drawn to” the site of inflammation by molecules on the surface of cells lining the local blood vessels (vascular endothelium).
- vascular endothelium vascular endothelium
- Such molecules are themselves expressed in response to cytokines released at the initial pathogen invasion site.
- These molecules bind to receptors on circulating blood cells and allow local adhesion and subsequent diapedesis into the invasion site.
- the adhesion molecules are known as intracellular adhesion molecules (ICAM) and a variety of these have been discovered. Blocking the expression and/or function of the various ICAM's has led to
- TLR's toll-like receptors
- TLR2/1; TLR2/6 and TLR4 lipids and lipopeptides
- proteins TLR5 and TLR11
- nucleic acids TLR3, 7, 8 and 9
- An ideal therapeutic agent to target and control mucosal inflammation would therefore be an agent with both acute and long-lasting effects on mucosa inflammation and may indeed be disease altering.
- the present invention addresses this.
- the present invention relates to, as a first aspect, a pharmaceutical composition
- a pharmaceutical composition comprising SEQ ID NO:1 with a cation optionally selected from the following list Na + , K + , Mg + , Ca ++ , Ba ++ , Mn ++ , Ni ++ , Li ++ , Zn ++ and Cr +++ , preferably Na + , more preferably 40-200 mM Na + , optionally including 2-20 mM Mg 2+ .
- the concentration range is preferably 40-200 mM for Na + or K + , and 2-20 mM for Mg ++ , Ca ++ , Ba ++ , Mn ++ , Ni ++ , Li ++ , Zn ++ or Cr +++ .
- the pharmaceutical composition may have a combination of 40-200 mM Na + and 2-20 mM Mg 2+ , or 40-200 mM Na + and 40-200 mM K + .
- the composition may comprise a combination of Na + and K + , or Na + and Mg ++ or Na + and Ca ++ or Na + and Ba ++ or Na + and Mn ++ or Na + and Ni ++ or Na + and Li′ or Na + and Zn ++ or Na + and Cr +++ , or K + and Mg ++ or K + and Ca ++ or K + and Ba ++ or K + and Mn ++ or K + and Ni ++ or K + and Li′ or K + and Zn ++ or K + and Cr +++ .
- composition of the first aspect may also comprise one or more of hydroxymethyl cellulose, methyl paraben sodium, propylparaben sodium, monobasic sodium phosphate monohydrate, sodium hydroxide, hydrochloric acid and/or water.
- the composition may be in the form of a liquid syrup, gel, film, cream, powder, tablet, enema and/or particulate, preferably which is suitable for inhalation.
- composition of the invention may be formulated as a gel, cream, lotion, solution, suspension, emulsion, ointment, powder or particulate which is suitable for inhalation, tablet, spray, aerosol, foam, salve, microparticle, nanoparticle, or bioadhesive, and may be prepared so as to contain liposomes, micelles and/or microspheres.
- composition may have the components in the following ranges
- SEQ ID NO: 1 4 mg hydroxymethyl cellulose 7-8 mg, optionally 7.5 mg methylparaben sodium 16.6 mM 2.8-3.0 mg propylparaben sodium 1.4 mM 0.28-3 mg monobasic sodium phosphate 4.4-4.6 mg monohydrate37.5 mM wherein the ranges given are per ml with a total of 60 ml per dose.
- the treatment is 4 mg/ml.
- the above specific dose may be a liquid enema formulation.
- a second aspect of the invention relates to the composition of the first aspect for use in medicine.
- the medicine may be human or veterinary.
- Veterinary medicine includes any animal including production and/or pet animals including, in particular dogs, cats and/or equine animals.
- the medicine may be for the prevention or treatment of inflammatory bowel disease, rectal stump disease, radiation-induced proctitis, pouchitis, asthma, inflammation of the eye, dry eye, rhinitis or sinusitis or graft versus host disease.
- a third aspect of the invention is the use of SEQ ID NO:1 in the manufacture of a medicament according to the first aspect of the invention for the prevention or treatment of inflammatory bowel disease, rectal stump disease, radiation-induced proctitis, pouchitis, asthma, inflammation of the eye, dry eye, graft versus host disease (GVHD), rhinitis or sinusitis.
- inflammatory bowel disease rectal stump disease
- radiation-induced proctitis pouchitis
- asthma inflammation of the eye
- dry eye dry eye
- graft versus host disease (GVHD) graft versus host disease
- a fourth aspect of the invention relates to a method of treating inflammatory bowel disease, rectal stump disease, radiation-induced proctitis, pouchitis, asthma, inflammation of the eye, dry eye, rhinitis, sinusitis, or grant-versus host disease, the method comprising administration of a composition of the first aspect of the invention to a patient in need thereof.
- the patient may be a human (adult or youth) or an animal.
- a fifth aspect of the invention relates to a method of making a composition of the first aspect of the invention, the method comprising combining SEQ ID NO:1 with a cation, optionally selected from the following list Na + , K + , Mg ++ , Ca ++ , Ba ++ , Mn ++ , Ni ++ , Li ++ , Zn ++ , and Cr +++ , preferably Na + , more preferably 40-200 mM Na + , optionally including 2-20 mM Mg 2+ .
- a cation optionally selected from the following list Na + , K + , Mg ++ , Ca ++ , Ba ++ , Mn ++ , Ni ++ , Li ++ , Zn ++ , and Cr +++ , preferably Na + , more preferably 40-200 mM Na + , optionally including 2-20 mM Mg 2+ .
- the invention provides a composition, according to the first aspect of the invention, as claimed in any one of claims 1 to 6 , wherein the composition is in the form of an enema and wherein the composition is formulated in a dosage form to provide a concentration of SEQ ID NO:1 at 4 mg/ml per day.
- composition may be in the form of an enema and wherein the composition is formulated in a dosage form to provide a concentration of SEQ ID NO:1 at 0.25-4 mg/ml per day.
- SEQ ID NO:1 is as follows: 5′-gcccaagctg gcatccgtca-3′.
- the antisense oligonucleotide SEQ ID NO:1 is also known as alicaforsen.
- the formulation can be prepared using components that cause the formulation to be a liquid at room temperature, but solidify to a gel state at body temperature.
- the formulation may be prepared as a liquid and applied to a mucosal surface, such as the nasal mucosa, followed by the application of an inert dry powder, such as methyl cellulose, to retain the formulation at the site of application.
- a dry powder formulation of the composition may be mixed with the inert dry powder and applied together at the mucosa site.
- the oligonucleotides SEQ ID NO:1 in accordance with this invention preferably comprises from about 20 to about 80 nucleic acid base units. It is more preferred that such oligonucleotides comprise from about 20 to 50 nucleic acid base units, still more preferred to have from about 20 to 30 nucleic acid base units, and most preferred to have from about 20 to 22 nucleic acid base units.
- a nucleic acid base unit is a base-sugar combination suitably bound to an adjacent nucleic acid base unit through phosphodiester or other bonds.
- nucleic acid base units includes 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79 or 80 nucleobase units.
- the composition comprises a fragment of SEQ ID NO:1, wherein the fragment is at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 nucleotides in length.
- the fragment can hybridise to a sequence in the 3′-untranslated region of the human ICAM-1 mRNA.
- the fragment can hybridise under moderate or stringent conditions with nucleotides ‘cctgacg gatgccagct tgg’ (SEQ ID NO:2).
- Fragments include ‘cccaagctg gcatccgtca’ (SEQ ID NO:3), ‘gcccaagctg gcatccgtc’ (SEQ ID NO:4) and ‘gcccaagctg gca’ (SEQ ID NO:5).
- “Stringency” of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridisable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).
- “Stringent conditions” or “highly stringent conditions”, may be identified by those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulphate at 50° C.; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42° C.; or (3) employ 50% formamide, 5 ⁇ SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 ⁇ Denhardt's solution, sonicated salmon sperm DNA (50 [mu]g/ml), 0.1% SDS, and 10% dextran
- Modely stringent conditions may be identified as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and % SDS) less stringent that those described above.
- washing solution and hybridization conditions e.g., temperature, ionic strength and % SDS
- An example of moderately stringent conditions is overnight incubation at 37° C.
- conditions of moderate or high stringency can be readily determined by those having ordinary skill in the art based on, for example, the length of the DNA.
- the basic conditions are set forth by Sambrook et al. Molecular Cloning: A Laboratory Manual, 2 ed. Vol. 1, pp. 1.101-104, Cold Spring Harbor Laboratory Press, (1989).
- the oligonucleotide can be modified to comprise at least one phosphorothioate linkage.
- Phosphorothioate modification of the oligonucleotide by substituting a sulfur molecule for a non-bridging oxygen molecule in each phosphodiester linkage, significantly increases exonuclease resistance relative to unmodified DNA and prolongs the drug half-life (Geary et al., Anti-Cancer Drug Design, 12:383-94, 1997).
- Phosphorothioate oligonucleotides are only minimally antigenic, non-cytotoxic and well tolerated, and their pharmacokinetic and pharmacodynamic properties are well characterized (see e.g., Butler et al., Lab.
- a suitable dose may be 2 mg/ml per day for example, per enema.
- a minimum dose would be 0.25 mg/mL per day for example, per enema.
- composition may be administered once, twice, three or four times a day or periodically.
- composition can be administered for 2, 3, 4, 5, 6, 7, 8 or more weeks.
- a suitable dose per treatment may be 0.05 mg to 400 mg.
- a treatment can be administered from once to eight times per day.
- a suitable dose concentration may be 0.5 mg/mL to 10 mg/mL.
- a suitable dose administered to asthma patients may be between 0.5 to 5 ml, in particular around 1 mL.
- a suitable dose administered to dry eye or inflammation of the eye patients may be between 1-100 ul, in particular around 50 ul.
- a suitable enema administered dose may be between 10 to 100 mL, in particular around 60 mL.
- composition may be administered once, twice, three, four, five, six, seven or eight times a day or periodically.
- composition can be administered for 1, 2, 3, 4, 5, 6, 7, 8 or more weeks.
- composition can be administered for 1, 2, 3, 4, 5 or 6 days.
- composition may be in respect of existing aggravation, inflammation, pain and/or discharge of the effected site or may be prophylactic (preventative treatment). Treatment may include curative, alleviation or prophylactic effects.
- diseases treatable by the invention include the mucosal inflammatory conditions described below.
- Each disease requires the influx of certain blood borne inflammatory cells and activation of immune cells that have localized to the site of inflammation.
- Such diseases are therefore ideally treated by an agent that can block both the influx of inflammatory cells and the activation of the innate immune system, as provided by the present invention.
- Inflammatory bowel diseases include ulcerative colitis (UC) and Crohn's disease (CD), both of which are inflammatory disorders of the intestinal mucosa. Ulcerative colitis is confined to the large intestine, while Crohn's disease can involve any region of the intestinal mucosa, including the oral cavity. Both UC and CD are characterized by the influx of inflammatory and immune cells in response to environmental and autoimmune stimuli. Although the histopathology of the two diseases differ, many therapeutic agents are used to treat both conditions, such as steroids, anti-TNF antibodies and mesalamine.
- Pouchitis is inflammation of the distal intestinal mucosa remaining after surgical removal of the colon and formation of a J-pouch by ileal-anal anastomosis. Mucosal inflammation in pouchitis is similar to that observed in ulcerative colitis, although it may have microbial involvement to a greater extant. It is characterized by influx of activated inflammatory cells and activation of the local immune system.
- Rectal stump disease is an inflammatory condition affecting the rectal mucosa remaining after colectomy.
- Asthma is a complex and multifactorial disorder typified by episodes of breathlessness and wheezing in concert with airway hyper-reactivity (AHR) to a range of stimuli.
- Chronic inflammation mucosa of the airway wall is thought to be the primary factor driving asthmatic exacerbations.
- Th2 polarized CD4 T helper 2
- cytokines secreted from these cells are largely responsible for acute exacerbations and promotion of the pathologic features of allergic asthma.
- TLR9 agonists As a potential therapy for asthma.
- Astra Zeneca have a TLR9 agonist AZD1419, in-licensed from Dynavax, in Phase 2a for patients with eosinophilic, moderate to severe asthma via inhaled route.
- the TLR9 agonist suppresses Th2 (late phase) responses and enhanced Th1 responses.
- TLR-9 agonist CYT003-QbG10 Cytos Biotechnology has run clinical trials using the TLR-9 agonist CYT003-QbG10 to treat allergic bronchial asthma.
- Eosinophilic sinusitis is an inflammation of the nasal mucosa characterized by the chronic influx of eosinophils and other monocytes and lymphocytes from the blood into the nasal mucosa in response to environmental antigens. This reaction leads to a variety of symptoms including nasal discharge (rhinorrea), congestion, nasal polyps. Eosinophilic sinusitis includes sinusitis and rhinitis.
- the paper explains how previous studies have strongly demonstrated a relationship between rhinosinusitis and asthma. This has led to the introduction of the concept of ‘United Airways’, which has also been included in the WHO document Allergic Rhinitis and its Impact on Asthma (ARIA); this concept has important consequences also on the treatment of these disorders.
- the present invention is used to treat eosinophilic sinusitis.
- Graft versus host disease occurs subsequent to bone marrow transplantation performed for treatment of blood cell cancers such as leukemia.
- the host blood-cell forming organs are eliminated by radiation treatment and the donor (graft) marrow transplanted to re-establish the organ's function. While this procedure can effectively treat the cancer, the transplanted immune system can begin to “reject” the host tissues.
- Sensitive tissues include the liver, skin, lungs and the GI tract. Systemic immunosuppression is used to control the rejection in most of these tissues, but the GI mucosa is particularly difficult to treat with systemic therapies. Inflammation occurring in the small intestine and colon is better treated with targeted therapy delivered directly to the gut lumen.
- the present invention in either an oral formulation or rectal enema formulation is used to suppress graft versus host disease.
- mice were myeloablative-irradiated and injected with 10 7 bone marrow cells and 4 ⁇ 10 7 splenocytes obtained from full MHC major and minor Ag-disparate BALB/c donors. Recipient mice were monitored for clinical signs of GVHD, weight and survival. Interestingly those mice with a TLR4 knockout did not show an improved survival versus wild type recipient mice.
- mice succumbed to severe acute GVHD within 60 days, while TLR9 ⁇ / ⁇ mice showed a significantly higher survival rate, with four of eight mice still alive at the end of the experiment.
- the GVHD clinical score in TLR9 ⁇ / ⁇ mice was also significantly lower than that in TLR 4 ⁇ / ⁇ and C57B/6 mice and this correlated with reduced intestinal damage in the small intestine and to a lesser effect in the large bowel in TLR9 ⁇ / ⁇ mice.
- all TLR9 ⁇ / ⁇ surviving mice achieved complete immune reconstitution, showed 100% donor peripheral blood lymphocyte cells. The results in this paper demonstrate the important role that TLR9 plays in the pathogenesis of GVHD.
- Inflammation of the eye can also be treated with the present invention.
- Such conditions are dry eye or Sjogren's disease where reduction in the production of tear fluid results in local inflammation of the ocular mucosa.
- Dry eye disease is a common complaint of ophthalmic patients. Unaddressed conditions of dry eye can lead to erosion and abrasion of the epithelial cell surface of the cornea, raising susceptibility to infection. Progression of the disease can lead to ulceration of the cornea, even loss of sight.
- Disease and some physical conditions can predispose individuals to dry eye disorder, including; allergies, diabetes, lacrimal gland deficiency, lupus, Parkinson's disease, Sjogren's syndrome, rheumatoid arthritis, rosacea, and others.
- Medications for other diseases may cause or exacerbate dry eye disorders, including diuretics, antidepressants, allergy medications, birth control pills, decongestants and others.
- Age related changes may induce or exacerbate dry eye as well.
- Post-menopausal women experience changes in hormonal levels that can instigate or worsen dry eye and thyroid imbalances may cause similar changes. Finally aging itself can cause reduction in lipid production with resultant dry eye.
- the present invention can be used for treating dry eyes, chronic dry eye (CDE) disease, or dry eye syndrome in a subject in need thereof.
- Subjects suffering from dry eyes, chronic dry eye (CDE) disease, or dry eye syndrome can be identified by any or a combination of diagnostic or prognostic assays known in the art.
- typical symptoms of dry eyes, chronic dry eye (CDE) disease, or dry eye syndrome include, but are not limited to, symptoms such as, e.g., stinging, burning, or scratchy sensation in the eyes, stringy mucus in or around the eyes, increased eye irritation from smoke or wind, eye fatigue, sensitivity to light, eye redness, sensation of foreign object in the eyes, difficulty wearing contact lenses, periods of excessive tearing, swollen eyes, eye discomfort, eye pain, and blurred vision (which worsens at the end of the day or after focusing for a prolonged period).
- symptoms such as, e.g., stinging, burning, or scratchy sensation in the eyes, stringy mucus in or around the eyes, increased eye irritation from smoke or wind, eye fatigue, sensitivity to light, eye redness, sensation of foreign object in the eyes, difficulty wearing contact lenses, periods of excessive tearing, swollen eyes, eye discomfort, eye pain, and blurred vision (which worsens at the end of the day or after focusing for a prolonged period).
- dry eyes is diagnosed by the tear osmolarity test.
- the tear osmolarity test measures the number of solid particles in a tear. The higher the tear osmolarity typically indicates that the tear has less water and more particles, e.g., salts, proteins, lipids, and mucin.
- the present invention can be used to treat mild dry eyes, moderate dry eyes, moderate to severe dry eyes and severe dry eyes.
- Symptoms of severe dry eye may include, amongst others, conjunctival injection (hyperemia); such as bulbar conjunctival hyperemia, inferior tarsal conjunctival hyperemia, nasal bulbar conjunctival hyperemia; lid margin hyperemia, central corneal staining and redness of the eye.
- conjunctival injection hyperemia
- bulbar conjunctival hyperemia inferior tarsal conjunctival hyperemia
- nasal bulbar conjunctival hyperemia nasal bulbar conjunctival hyperemia
- lid margin hyperemia central corneal staining and redness of the eye.
- treatment includes “therapeutic” and “prophylactic” and these types of treatment are to be considered in their broadest context.
- therapeutic does not necessarily imply that a subject is treated until total recovery.
- prophylactic does not necessarily mean that the subject will not eventually contract a disease condition.
- therapeutic and prophylactic treatment includes amelioration of the symptoms of a particular condition or preventing or otherwise reducing the risk of developing a particular condition.
- the term “prophylactic” may be considered as reducing the severity or the onset of a particular condition. “Prophylactic” also includes preventing reoccurrence of a particular condition in a patient previously diagnosed with the condition. “Therapeutic” may also reduce the severity of an existing condition.
- TLRs are a key means by which the host recognizes and mounts an immune response to foreign molecules. They also provide a mechanism by which the innate and adaptive immune responses are linked. Specifically, TLR-9 recognizes bacterial and viral DNA through certain unmethylated CpG motifs not present in mammalian DNA. Cells contained within the mucosa can therefore “sense” and respond to the presence of “foreign” DNA. Binding of such ligands activates the immune system to further respond to and remove the pathogen.
- synthetic oligonucleotides containing CpG dinucleotide sequences can stimulate immune responses through the TLR-9 pathway.
- ODN synthetic oligonucleotides
- the use of synthetic oligonucleotides has shown utility as inhibitors of inflammatory cytokines and these actions are known to be mediated though inhibitory actions on TLR-9.
- GGGG GGGG
- TTAGGG elements present at high frequency in mammalian telomeres, have been observed to down-regulate CpG-induced immune activation demonstrate that synthetic oligonucleotides containing the TTAGGG element mimic this activity and could be effective in the prevention/treatment of certain Th1-dependent autoimmune diseases.
- ODNs have also been studied as a basis for defining the DNA structure necessary for binding to TLR-9. However, there does not appear to be a secondary structure that absolutely specifies binding affinity, although sequence specific effects on structure are observed to alter the ODN agonist or antagonist activity.
- SEQ ID NO:1 is an antagonist of TLR-9 and is devoid of agonist activity. Further, the invention defines specific conditions that contribute to the predicted secondary structure of SEQ ID NO:1 and relate the secondary structure to TLR-9 antagonism.
- FIG. 1 is a dose response graph for SEQ ID NO:1 stimulation of TLR-9.
- FIG. 2 is a dose response of TLR-9 inhibition by SEQ ID NO:1.
- FIG. 3 is a graph showing SEQ ID NO:1 inhibition curves for ICAM-1 and TLR-9.
- FIG. 4 is a thermodynamic predication of duplex stability for SEQ ID NO:1 and ODN2006 hetero duplex vs SEQ ID NO:1 homo duplex.
- FIG. 5 is a graph showing the inhibition of TLR-9 activated by E. coli genomic DNA.
- FIG. 6 shows: Upper—CD spectra of SEQ ID NO:1 in ddH20 at 4° C. Lower—spectra 20-95° C.
- FIG. 7 a shows a 190 nm peak intensity as a function of temperature.
- FIG. 7 b shows a 220 nm peak intensity as a function of temperature.
- FIG. 8 shows the spectra of SEQ ID NO:1 in 5 mM spermine.
- FIG. 9 shows a schematic of the experimental set up.
- FIG. 10 shows IC50's for SEQ ID NO:1 inhibition of ODN2006 activation of TLR-9.
- FIG. 11 shows the Corneal Fluorescein Staining (CFS) evaluation of alicaforsen (1 mM and 10 mM dose) in scopolamine dry eye mouse model at day 6 and day 10. Each circle represents one eye and the line is the mean of the group. Two-way and one-way ANOVA Analyses were performed followed by Dunnett's Tests for multiple comparisons * p ⁇ 0.05; ** p ⁇ 0.001.
- CFS Corneal Fluorescein Staining
- FIG. 12 shows the evaluation of alicaforsen in Ovalbumin-Induced Murine Model of Allergic Asthma.
- the present invention provides the following examples which are not limiting.
- SEQ ID NO:1 was screened for dose response activity to determine possible EC50 for TLR9 activation at seven different doses (0.01, 0.05, 0.1, 0.5, 1, 5 and 10 ⁇ M) in triplicate. Briefly, the TLR9/NF-kB luciferase reporter HEK 293 cell line (Abeomics, San Diego, Calif.) was plated in 96-well white solid plates at 5 ⁇ 10 4 cells per well for 16 h. Cells were treated with different doses of SEQ ID NO:1 as well as with 20 ug/ml of CpG ODN-2006, a known agonist of TLR-9 in triplicate for 16 h. Luciferase activity was then measured and analyzed.
- SEQ ID NO:1 was devoid of agonist activity up to concentrations as high as 100 uM while a 1.0 uM dose of ODN2006 produced a 7.5-fold increase in TLR-9 induced gene activation.
- SEQ ID NO:1 was next screened for dose responsive inhibition activity to determine the IC50 against TLR9-mediated NF-kB induction at seven different doses (0.1, 1, 5, 10, 25, 50 and 100 ⁇ M) in triplicate. Briefly, the TLR9/NF-kB luciferase reporter HEK 293 cell line was plated in 96-well white solid plates at 5 ⁇ 10 4 cells per well for 16 h. Cells were pretreated with different doses of SEQ ID NO:1 in triplicate for 1 h. Cells were then treated with 20 ug/ml of CpG ODN2006 to activate TLR9. After 16 h, luciferase activity was measured and analyzed. These results are shown in FIG. 2 .
- SEQ ID NO:1 As an antagonist of TLR-9 requires higher concentrations than the inhibition of ICAM-1 expression.
- the comparative dose responses are shown in FIG. 3 , in relation to the dose used in the enema formulation.
- the homodimer shown in FIG. 4 is the most energetically favorable duplex structure for SEQ ID NO:1. Of interest was whether this secondary structure may influence the TLR-9 inhibitory activity and under which conditions the duplex was most stable
- the predicted duplex structure is stabilized by 4 Watson-Crick type bonds flanked by G-A mismatches and another 2 G-C pairs.
- the CpG motifs remain unconstrained on the non-overlapping 3′ ends for each duplex member.
- CD of DNA can be utilized to detect all 3 major forms of duplex structure (B, A and Z) and is sensitive to conditions that disrupt the structure such a heating. Of interest was the stability of any secondary structure detected at or above physiologic temperatures.
- Shown in FIG. 6 is the CD spectra of sample SEQ ID NO:1 in ddH20 at 4C.
- the profile shows features characteristic of duplexes in the B-form of DNA, namely a characteristic low intensity positive band at ⁇ 280 nm, two low intensity negative bands at ⁇ 210 nm and ⁇ 255 nm and an positive intense band at ⁇ 190 nm
- the positive band at 190 nm was found to be sensitive to temperature between 4° C. and 20° C. Further heating to 80° C. showed a loss of >85% of the signal strength. This background signal was achieved at 40° C. making it unlikely that the structure is stable to physiological temperature under these conditions.
- the intensity of the 190 nm peak is more stable to heating under both 50 and 150 mM sodium conditions, retaining at least 50% of its structure to 40° C.
- the intensity of the 190 nm peak returned to pre-heated levels once the samples were cooled back to 20° C. This implies that the observed secondary structure is reversible after melting.
- samples of SEQ ID NO:1 were dissolved in Tris buffer at pH 7.2 including 50 mM NaCl, in the presence of either 15 mM Mg ++ or 5 mM spermine or both Mg ++ and spermine.
- Tris buffer pH 7.2 including 50 mM NaCl
- One sample remained at room temperature while the remaining samples were heated to 90° C. for 3 min and then allowed to cool to room temperature.
- the samples were then diluted to the indicated concentrations and incubated with the target cells for 1 hr, prior to the addition of 1.0 uM ODN2006 to stimulate TLR-9.
- the results of the experiment are shown in FIG. 10 .
- transdermal scopolamine patches In a model of mice, the application of transdermal scopolamine patches to the mid-tail is used to reduce aqueous tear production and thus mimic lacrimal gland insufficiency.
- the function of scopolamine is to induce a pharmacologic blockade of cholinergic receptors in the lacrimal gland and therefore to decrease aqueous production.
- the desiccation is amplified by adding environmental stress. Animals are exposed to a low-humidity environment and constant airflow.
- mice 40 animals were included in this study. Animals were selected based on good health and homogeneous body weight. Only healthy animals without visible ocular defect (corneal opacity) were involved in this study. Animals were randomized into the study groups using a macro function in Excel® software on the basis of the mean of the corneal fluorescein staining scores from both eyes on Day 3.
- Dry eye symptoms were induced in pigmented C57BL/6N mice by exposing them to a controlled environment room (approximate relative humidity ⁇ 25%, temperature 22° C. ⁇ 2° C.), in a cage with an air-flow around 15 L/min and transdermal scopolamine administration (0.5 mg/72 h) for eleven days.
- mice were treated with transdermal scopolamine administration (0.5 mg/72 h; Scopoderm TTS®).
- the transdermal scopolamine patch was wrapped near the tail base of the mouse, secured with cellophane tape. Patches were reapplied every 48 hours.
- mice were randomized into 4 groups of 10 animals. The study was divided into 2 experimental sets with 5 animals of each group represented. All mice were treated on day one and then treated for 10 days in total according to the following regime:
- test items, control items and comparator item were instilled in both eyes (5 ⁇ L per administration), using a micropipette.
- alicaforsen (10 mM and 1 mM), Vehicle, and Optimmune® did not affect the behaviour of the animals.
- the Vehicle group had dry eye symptoms from Day 3 to Day 10, showing that this study is validated.
- the Vehicle group had dry eye symptoms from Day 3 to Day 10, showing that this study is validated.
- Optimmune® 0.2% and alicaforsen (1 mM) groups showed a statistically significant reduction in the dry eye symptoms as measured by corneal fluorescein staining
- OVA ovalbumin
- Allergic asthma was modeled in female BALB/c mice by initial sensitization to OVA followed by subsequent intranasal challenge of purified OVA.
- mice were monitored throughout the study for changes in body weight and general signs of sickness. Allergic response to OVA was measured by examining bronchoalveolar lavage fluid (BALF) for inflammatory cell influx and the presence of the inflammatory cytokine IL-13.
- BALF bronchoalveolar lavage fluid
- mice in experimental groups were treated via intranasal (IN) administration of either alicaforsen, at 1 mM dosing concentration, control vehicle (PBS), or intraperitoneal (IP) dexamethasone as a positive anti-inflammatory control.
- IN intranasal
- PBS control vehicle
- IP intraperitoneal
- Table 2 and 3 below detail the test items and test materials used during the study.
- dexamethasone stock solution (4 mg/mL) was added to 3 mL saline for a solution concentration of 1 mg/mL.
- OVA Chicken egg OVAlbumin
- Species/Strain Balb/c Gender: Female Total # of 55 Animals: Age: 7-8 weeks of age at study initiation. Body Weight: Weight variation of the animals at study initiation did not exceed ⁇ 20% of the mean weight.
- Animals Health The health status of the animals used in this study was examined on arrival. All animals were in good health, were acclimatized to laboratory conditions, and were used in the study. Acclimation: At least 72 hours. Housing: During acclimation and study, animals were housed within a limited access rodent facility and kept in groups of maximum 5 mice. Mice were housed in sterilized individually ventilated polysulfone cages with irradiated cob bedding material.
- Food and Water Animals were provided ad libitum a commercial rodent diet and free access to drinking water, supplied to each cage via sterilised polyethylene bottles. All food and water is sterilised. Environment: Automatically controlled environmental conditions were set to maintain temperature at 20-26° C. with relative humidity (RH) of 30-70%, a 12:12 hour light:dark cycle. Randomisation: Animals were randomly assigned to cages on arrival. Animals were assigned to treatment groups on day ⁇ 1. Termination: Euthanasia anesthesia overdose.
- each animal was administered an IP injection of 200 ⁇ L OVA/Alum emulsion containing 100 ⁇ g OVA.
- each animal was administered an intranasal challenge of 30 ⁇ L PBS containing 50 ⁇ g OVA.
- alicaforsen was administered at 1 mM concentration intra-nasally (IN) in a volume of 30 ⁇ L. Treatments were performed on the same days as OVA challenge on Study Days 14 and 25-27 (4 total treatments). Treatments were administered 1 hour following OVA challenge.
- I intra-nasally
- Body weight of animals was determined shortly before the study commencement and twice weekly thereafter.
- mice On Day 28, all mice were euthanised via detamine+xylazine overdose and exsanguination.
- Bonchoalveolar lavage was performed on euthanised animals. Briefly, an angiocatheter was placed into trachea. 1 mL of PBS was instilled into the lungs and allowed to flow back out into the syringe; the PBS was then instilled and removed again. The resultant Bronchoalveolar lavage fluid (BALF) was centrifuged at 500 ⁇ g for 5 mins.
- BALF Bronchoalveolar lavage fluid
- the non-cellular portion of the BALF was stored at ⁇ 80° C.
- the levels of IL-13 were analyzed by Luminex technology.
- the cellular portion of the BALF was used to analyze the cell influx.
- the total number of leukocytes within the BALF and different cell types present were examined via flow cytometry.
- Granulocytes CD45 + ; Non-autofluorescent; Gr-1 + Eosinophils: CD45 + ; Non-autofluorescent; Gr-1 + ; Siglec F +
- Animals sensitized and challenged with OVA protein showed signs of disease at experiment termination, including significantly increased alveolar influx of total leukocytes, granulocytes and eosinophils when compared to na ⁇ ve mice. Furthermore, diseased animals showed significantly increased levels of IL-13 in BALF.
Abstract
The present invention relates to a new formulation of the oligonucleotide of SEQ ID NO: 1.
Description
- The present invention relates to a new formulation of the oligonucleotide of SEQ ID NO: 1.
- Mucosal surfaces represent the first interface between the internal environment of the host organism and the external environment. Mucosal surfaces are therefore enriched in a variety of cellular and acellular structures that protect the host from foreign pathogen or antigen exposure. These important surfaces are represented by the mucosal surfaces of the oral and nasal (sinus) cavity, the pulmonary and digestive systems and mucosal tissues surrounding the eye.
- The cells comprising the mucosa are equipped to sense and respond to a variety of foreign substances. These cells also elaborate a variety of molecular pathways to communicate such invasion to the surrounding tissues and recruit an influx of additional inflammatory and immune cells to fight the infection, repair damage and if necessary induce specific immune responses in the form of antibodies. While these mechanisms serve an important and indeed life-saving function for the organism, their chronic and/or misguided activation can lead to considerable morbidity and mortality.
- The chronic influx of inflammatory cells and the subsequent local activation of cells of the immune system are two primary loci where chronic mucosal inflammation can be controlled. These responses are part of the “innate immune system”. The first responding cells of the innate immune system, such as dendritic cells and macrophages, ingest pathogens and release cytokines drawing secondary, active and defensive cells from the blood. These secondary invading cells must be “drawn to” the site of inflammation by molecules on the surface of cells lining the local blood vessels (vascular endothelium). Such molecules are themselves expressed in response to cytokines released at the initial pathogen invasion site. These molecules bind to receptors on circulating blood cells and allow local adhesion and subsequent diapedesis into the invasion site. The adhesion molecules are known as intracellular adhesion molecules (ICAM) and a variety of these have been discovered. Blocking the expression and/or function of the various ICAM's has led to the development of several therapeutic products to suppress inflammatory diseases.
- Cells of the innate immune system also have a well-developed repertoire of surface receptors that sense and bind microbial components expressed by bacteria, viruses, fungi and other pathogens. These receptors have been termed “toll-like receptors” (TLR's) and as many as 12 members of this family are now known in the human genome. Pathogen-encoded TLR ligands fall into three broad categories: lipids and lipopeptides (TLR2/1; TLR2/6 and TLR4), proteins (TLR5 and TLR11) and nucleic acids (TLR3, 7, 8 and 9). Therapeutic targeting of certain TLR's has been exploited as a means to stimulate the immune system (vaccine production) and agents targeting other TLR's are being developed to inhibit certain immune functions.
- An ideal therapeutic agent to target and control mucosal inflammation would therefore be an agent with both acute and long-lasting effects on mucosa inflammation and may indeed be disease altering.
- The present invention addresses this.
- The present invention relates to, as a first aspect, a pharmaceutical composition comprising SEQ ID NO:1 with a cation optionally selected from the following list Na+, K+, Mg+, Ca++, Ba++, Mn++, Ni++, Li++, Zn++ and Cr+++, preferably Na+, more preferably 40-200 mM Na+, optionally including 2-20 mM Mg2+. The concentration range is preferably 40-200 mM for Na+ or K+, and 2-20 mM for Mg++, Ca++, Ba++, Mn++, Ni++, Li++, Zn++ or Cr+++. For example, the pharmaceutical composition may have a combination of 40-200 mM Na+ and 2-20 mM Mg2+, or 40-200 mM Na+ and 40-200 mM K+. For example the composition may comprise a combination of Na+ and K+, or Na+ and Mg++ or Na+ and Ca++ or Na+ and Ba++ or Na+ and Mn++ or Na+ and Ni++ or Na+ and Li′ or Na+ and Zn++ or Na+ and Cr+++, or K+ and Mg++ or K+ and Ca++ or K+ and Ba++ or K+ and Mn++ or K+ and Ni++ or K+ and Li′ or K+ and Zn++ or K+ and Cr+++.
- The composition of the first aspect may also comprise one or more of hydroxymethyl cellulose, methyl paraben sodium, propylparaben sodium, monobasic sodium phosphate monohydrate, sodium hydroxide, hydrochloric acid and/or water.
- The composition may be in the form of a liquid syrup, gel, film, cream, powder, tablet, enema and/or particulate, preferably which is suitable for inhalation.
- The composition of the invention may be formulated as a gel, cream, lotion, solution, suspension, emulsion, ointment, powder or particulate which is suitable for inhalation, tablet, spray, aerosol, foam, salve, microparticle, nanoparticle, or bioadhesive, and may be prepared so as to contain liposomes, micelles and/or microspheres.
- The composition may have the components in the following ranges
-
SEQ ID NO: 1 4 mg hydroxymethyl cellulose 7-8 mg, optionally 7.5 mg methylparaben sodium 16.6 mM 2.8-3.0 mg propylparaben sodium 1.4 mM 0.28-3 mg monobasic sodium phosphate 4.4-4.6 mg monohydrate37.5 mM
wherein the ranges given are per ml with a total of 60 ml per dose. Thus, in a treatment of 240 mg in 60 ml, the treatment is 4 mg/ml. The above specific dose may be a liquid enema formulation. - A second aspect of the invention relates to the composition of the first aspect for use in medicine. The medicine may be human or veterinary. Veterinary medicine includes any animal including production and/or pet animals including, in particular dogs, cats and/or equine animals.
- According to the second aspect of the invention, the medicine may be for the prevention or treatment of inflammatory bowel disease, rectal stump disease, radiation-induced proctitis, pouchitis, asthma, inflammation of the eye, dry eye, rhinitis or sinusitis or graft versus host disease.
- A third aspect of the invention is the use of SEQ ID NO:1 in the manufacture of a medicament according to the first aspect of the invention for the prevention or treatment of inflammatory bowel disease, rectal stump disease, radiation-induced proctitis, pouchitis, asthma, inflammation of the eye, dry eye, graft versus host disease (GVHD), rhinitis or sinusitis.
- All features of the first aspect of the invention also apply to the third aspect.
- A fourth aspect of the invention relates to a method of treating inflammatory bowel disease, rectal stump disease, radiation-induced proctitis, pouchitis, asthma, inflammation of the eye, dry eye, rhinitis, sinusitis, or grant-versus host disease, the method comprising administration of a composition of the first aspect of the invention to a patient in need thereof.
- All features of the first aspect of the invention also apply to the fourth aspect. The patient may be a human (adult or youth) or an animal.
- A fifth aspect of the invention relates to a method of making a composition of the first aspect of the invention, the method comprising combining SEQ ID NO:1 with a cation, optionally selected from the following list Na+, K+, Mg++, Ca++, Ba++, Mn++, Ni++, Li++, Zn++, and Cr+++, preferably Na+, more preferably 40-200 mM Na+, optionally including 2-20 mM Mg2+.
- Methods for making this new composition are standard methods as known in the art.
- The invention provides a composition, according to the first aspect of the invention, as claimed in any one of
claims 1 to 6, wherein the composition is in the form of an enema and wherein the composition is formulated in a dosage form to provide a concentration of SEQ ID NO:1 at 4 mg/ml per day. - The composition may be in the form of an enema and wherein the composition is formulated in a dosage form to provide a concentration of SEQ ID NO:1 at 0.25-4 mg/ml per day.
- SEQ ID NO:1 is as follows: 5′-gcccaagctg gcatccgtca-3′.
- The antisense oligonucleotide SEQ ID NO:1 is also known as alicaforsen.
- Certain enhancements to the formulation containing the oligonucleotides of SEQ ID NO:1 may also be necessary to aid in the retention of the active ingredient at the site of application. For example, the formulation can be prepared using components that cause the formulation to be a liquid at room temperature, but solidify to a gel state at body temperature. In other instances, the formulation may be prepared as a liquid and applied to a mucosal surface, such as the nasal mucosa, followed by the application of an inert dry powder, such as methyl cellulose, to retain the formulation at the site of application. In other instances, a dry powder formulation of the composition may be mixed with the inert dry powder and applied together at the mucosa site.
- The oligonucleotides SEQ ID NO:1 in accordance with this invention preferably comprises from about 20 to about 80 nucleic acid base units. It is more preferred that such oligonucleotides comprise from about 20 to 50 nucleic acid base units, still more preferred to have from about 20 to 30 nucleic acid base units, and most preferred to have from about 20 to 22 nucleic acid base units. As will be appreciated, a nucleic acid base unit is a base-sugar combination suitably bound to an adjacent nucleic acid base unit through phosphodiester or other bonds. One skilled in the art will understand that about 20 to about 80 nucleic acid base units includes 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79 or 80 nucleobase units.
- In a further embodiment, the composition comprises a fragment of SEQ ID NO:1, wherein the fragment is at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 nucleotides in length. The fragment can hybridise to a sequence in the 3′-untranslated region of the human ICAM-1 mRNA. The fragment can hybridise under moderate or stringent conditions with nucleotides ‘cctgacg gatgccagct tgg’ (SEQ ID NO:2). Fragments include ‘cccaagctg gcatccgtca’ (SEQ ID NO:3), ‘gcccaagctg gcatccgtc’ (SEQ ID NO:4) and ‘gcccaagctg gca’ (SEQ ID NO:5).
- “Stringency” of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridisable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).
- As herein defined, “Stringent conditions” or “highly stringent conditions”, may be identified by those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulphate at 50° C.; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42° C.; or (3) employ 50% formamide, 5×SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5×Denhardt's solution, sonicated salmon sperm DNA (50 [mu]g/ml), 0.1% SDS, and 10% dextran sulphate at 42° C., with washes at 42° C. in 0.2×SSC (sodium chloride/sodium citrate) and 50% formamide at 55° C., followed by a high-stringency wash consisting of 0.1×SSC containing EDTA at 55° C.
- “Moderately stringent conditions” may be identified as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and % SDS) less stringent that those described above. An example of moderately stringent conditions is overnight incubation at 37° C. in a solution comprising: 20% formamide, 5×SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5×Denhardt's solution, 10% dextran sulphate, and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1×SSC at about 37-50° C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.
- As used herein, conditions of moderate or high stringency can be readily determined by those having ordinary skill in the art based on, for example, the length of the DNA. The basic conditions are set forth by Sambrook et al. Molecular Cloning: A Laboratory Manual, 2 ed. Vol. 1, pp. 1.101-104, Cold Spring Harbor Laboratory Press, (1989).
- The oligonucleotide can be modified to comprise at least one phosphorothioate linkage. Phosphorothioate modification of the oligonucleotide, by substituting a sulfur molecule for a non-bridging oxygen molecule in each phosphodiester linkage, significantly increases exonuclease resistance relative to unmodified DNA and prolongs the drug half-life (Geary et al., Anti-Cancer Drug Design, 12:383-94, 1997). Phosphorothioate oligonucleotides are only minimally antigenic, non-cytotoxic and well tolerated, and their pharmacokinetic and pharmacodynamic properties are well characterized (see e.g., Butler et al., Lab. Invest, 77:379-88, 1997; Mirabelli et al., Anti-Cancer Drug Des., 6:647-61, 1991). In addition to phosphorothioate backbone modifications, a number of other possible backbone, sugar and other modifications are well known to those skilled in the art.
- The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g., decisions on dosage etc., is ultimately within the responsibility and at the discretion of general practitioners and other medical doctors, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners.
- For example, in one embodiment, a suitable dose may be 2 mg/ml per day for example, per enema.
- In another embodiment, a minimum dose would be 0.25 mg/mL per day for example, per enema.
- The composition may be administered once, twice, three or four times a day or periodically.
- The composition can be administered for 2, 3, 4, 5, 6, 7, 8 or more weeks.
- For example, in one embodiment, a suitable dose per treatment may be 0.05 mg to 400 mg. A treatment can be administered from once to eight times per day.
- A suitable dose concentration may be 0.5 mg/mL to 10 mg/mL. A suitable dose administered to asthma patients may be between 0.5 to 5 ml, in particular around 1 mL. A suitable dose administered to dry eye or inflammation of the eye patients may be between 1-100 ul, in particular around 50 ul. A suitable enema administered dose may be between 10 to 100 mL, in particular around 60 mL.
- The composition may be administered once, twice, three, four, five, six, seven or eight times a day or periodically.
- The composition can be administered for 1, 2, 3, 4, 5, 6, 7, 8 or more weeks.
- The composition can be administered for 1, 2, 3, 4, 5 or 6 days.
- The composition may be in respect of existing aggravation, inflammation, pain and/or discharge of the effected site or may be prophylactic (preventative treatment). Treatment may include curative, alleviation or prophylactic effects.
- Specific examples of diseases treatable by the invention include the mucosal inflammatory conditions described below. Each disease requires the influx of certain blood borne inflammatory cells and activation of immune cells that have localized to the site of inflammation. Such diseases are therefore ideally treated by an agent that can block both the influx of inflammatory cells and the activation of the innate immune system, as provided by the present invention.
- Inflammatory bowel diseases include ulcerative colitis (UC) and Crohn's disease (CD), both of which are inflammatory disorders of the intestinal mucosa. Ulcerative colitis is confined to the large intestine, while Crohn's disease can involve any region of the intestinal mucosa, including the oral cavity. Both UC and CD are characterized by the influx of inflammatory and immune cells in response to environmental and autoimmune stimuli. Although the histopathology of the two diseases differ, many therapeutic agents are used to treat both conditions, such as steroids, anti-TNF antibodies and mesalamine.
- Pouchitis is inflammation of the distal intestinal mucosa remaining after surgical removal of the colon and formation of a J-pouch by ileal-anal anastomosis. Mucosal inflammation in pouchitis is similar to that observed in ulcerative colitis, although it may have microbial involvement to a greater extant. It is characterized by influx of activated inflammatory cells and activation of the local immune system.
- Rectal stump disease is an inflammatory condition affecting the rectal mucosa remaining after colectomy.
- Asthma is a complex and multifactorial disorder typified by episodes of breathlessness and wheezing in concert with airway hyper-reactivity (AHR) to a range of stimuli. Chronic inflammation mucosa of the airway wall is thought to be the primary factor driving asthmatic exacerbations. It is now well established that polarized CD4 T helper 2 (Th2) cells infiltrate and accumulate in the bronchial mucosa of allergic asthmatics, and that cytokines secreted from these cells (interleukin-(IL)-4, IL-5, IL-9 and IL-13) are largely responsible for acute exacerbations and promotion of the pathologic features of allergic asthma. Inhibiting the influx of inflammatory cells, through down-regulation of ICAM-1 and suppression of the innate immune response through inhibition of TLR-9 is an effective therapeutic approach provided by the present invention. This was a surprising discovery as several studies have identified TLR9 agonists as a potential therapy for asthma. Several clinical trials have explored the use of TLR9 agonists to treat asthma, for example, Astra Zeneca have a TLR9 agonist AZD1419, in-licensed from Dynavax, in Phase 2a for patients with eosinophilic, moderate to severe asthma via inhaled route. The TLR9 agonist suppresses Th2 (late phase) responses and enhanced Th1 responses. Cytos Biotechnology has run clinical trials using the TLR-9 agonist CYT003-QbG10 to treat allergic bronchial asthma. Other TLR9 agonists which have been evaluated in the clinic for treating asthma were AIC (Dynavax), AVE0675 and SAR-21609 (Sanofi-Aventis/Coley Pharmaceuticals); QAX-935 (Idera Pharmaceuticals/Novartis).
- Eosinophilic sinusitis (ES) is an inflammation of the nasal mucosa characterized by the chronic influx of eosinophils and other monocytes and lymphocytes from the blood into the nasal mucosa in response to environmental antigens. This reaction leads to a variety of symptoms including nasal discharge (rhinorrea), congestion, nasal polyps. Eosinophilic sinusitis includes sinusitis and rhinitis. A paper by Licari A et al., (International Journal of Immunopathology Pharmacology, 2014 October-December; 27(4):499-508) explains how the upper and lower airways may be considered as a unique entity, interconnected by coexisting inflammatory processes that share common etiopathogenic mechanisms. The paper explains how previous studies have strongly demonstrated a relationship between rhinosinusitis and asthma. This has led to the introduction of the concept of ‘United Airways’, which has also been included in the WHO document Allergic Rhinitis and its Impact on Asthma (ARIA); this concept has important consequences also on the treatment of these disorders. The present invention is used to treat eosinophilic sinusitis.
- Graft versus host disease occurs subsequent to bone marrow transplantation performed for treatment of blood cell cancers such as leukemia. During transplantation, the host blood-cell forming organs are eliminated by radiation treatment and the donor (graft) marrow transplanted to re-establish the organ's function. While this procedure can effectively treat the cancer, the transplanted immune system can begin to “reject” the host tissues. Sensitive tissues include the liver, skin, lungs and the GI tract. Systemic immunosuppression is used to control the rejection in most of these tissues, but the GI mucosa is particularly difficult to treat with systemic therapies. Inflammation occurring in the small intestine and colon is better treated with targeted therapy delivered directly to the gut lumen. The present invention in either an oral formulation or rectal enema formulation is used to suppress graft versus host disease.
- In a paper by Calcaterra et al, in the Journal of Immunology, (2008, 181, 6132-6139) the authors demonstrate that inhibition of TLR9 may lead to the treatment of GVHD. The authors used C57BL/6 knockout mice to demonstrate that when TLR9 knockout mice were used as graft recipients, survival improved compared to wild type recipient mice. Mice were myeloablative-irradiated and injected with 107 bone marrow cells and 4×107 splenocytes obtained from full MHC major and minor Ag-disparate BALB/c donors. Recipient mice were monitored for clinical signs of GVHD, weight and survival. Interestingly those mice with a TLR4 knockout did not show an improved survival versus wild type recipient mice. All wild-type and TLR4−/− mice succumbed to severe acute GVHD within 60 days, while TLR9−/− mice showed a significantly higher survival rate, with four of eight mice still alive at the end of the experiment. The GVHD clinical score in TLR9−/− mice was also significantly lower than that in
TLR 4−/− and C57B/6 mice and this correlated with reduced intestinal damage in the small intestine and to a lesser effect in the large bowel in TLR9−/− mice. Finally, at the end of the experiment, all TLR9−/− surviving mice achieved complete immune reconstitution, showed 100% donor peripheral blood lymphocyte cells. The results in this paper demonstrate the important role that TLR9 plays in the pathogenesis of GVHD. - Inflammation of the eye can also be treated with the present invention. Such conditions are dry eye or Sjogren's disease where reduction in the production of tear fluid results in local inflammation of the ocular mucosa. Dry eye disease is a common complaint of ophthalmic patients. Unaddressed conditions of dry eye can lead to erosion and abrasion of the epithelial cell surface of the cornea, raising susceptibility to infection. Progression of the disease can lead to ulceration of the cornea, even loss of sight. Disease and some physical conditions can predispose individuals to dry eye disorder, including; allergies, diabetes, lacrimal gland deficiency, lupus, Parkinson's disease, Sjogren's syndrome, rheumatoid arthritis, rosacea, and others. Medications for other diseases may cause or exacerbate dry eye disorders, including diuretics, antidepressants, allergy medications, birth control pills, decongestants and others. Age related changes may induce or exacerbate dry eye as well. Post-menopausal women experience changes in hormonal levels that can instigate or worsen dry eye and thyroid imbalances may cause similar changes. Finally aging itself can cause reduction in lipid production with resultant dry eye.
- The present invention can be used for treating dry eyes, chronic dry eye (CDE) disease, or dry eye syndrome in a subject in need thereof. Subjects suffering from dry eyes, chronic dry eye (CDE) disease, or dry eye syndrome can be identified by any or a combination of diagnostic or prognostic assays known in the art. For example, typical symptoms of dry eyes, chronic dry eye (CDE) disease, or dry eye syndrome include, but are not limited to, symptoms such as, e.g., stinging, burning, or scratchy sensation in the eyes, stringy mucus in or around the eyes, increased eye irritation from smoke or wind, eye fatigue, sensitivity to light, eye redness, sensation of foreign object in the eyes, difficulty wearing contact lenses, periods of excessive tearing, swollen eyes, eye discomfort, eye pain, and blurred vision (which worsens at the end of the day or after focusing for a prolonged period).
- In some embodiments, dry eyes is diagnosed by the tear osmolarity test. The tear osmolarity test measures the number of solid particles in a tear. The higher the tear osmolarity typically indicates that the tear has less water and more particles, e.g., salts, proteins, lipids, and mucin. A tear osmolarity score of below 308 mOsms/L is normal, 308-320 mOsms/L is mild dry eyes, 320-340 mOsms/L is moderate dry eyes, and above 340 mOsms/L is severe dry eye. The present invention can be used to treat mild dry eyes, moderate dry eyes, moderate to severe dry eyes and severe dry eyes.
- Symptoms of severe dry eye may include, amongst others, conjunctival injection (hyperemia); such as bulbar conjunctival hyperemia, inferior tarsal conjunctival hyperemia, nasal bulbar conjunctival hyperemia; lid margin hyperemia, central corneal staining and redness of the eye.
- More specifically, treatment includes “therapeutic” and “prophylactic” and these types of treatment are to be considered in their broadest context. The term “therapeutic” does not necessarily imply that a subject is treated until total recovery. Similarly, “prophylactic” does not necessarily mean that the subject will not eventually contract a disease condition.
- Accordingly, therapeutic and prophylactic treatment includes amelioration of the symptoms of a particular condition or preventing or otherwise reducing the risk of developing a particular condition. The term “prophylactic” may be considered as reducing the severity or the onset of a particular condition. “Prophylactic” also includes preventing reoccurrence of a particular condition in a patient previously diagnosed with the condition. “Therapeutic” may also reduce the severity of an existing condition.
- In summary, the present invention provides details describing that:
-
- Mucosal inflammation can be more effectively treated by agents that can target multiple pathways in the innate immune system.
- Blocking the influx of inflammatory/immune cells (ICAM-1) and blocking the activation of the innate immune response (TLR-9) together allows both an acute and durable response.
- The 20-base oligonucleotide SEQ ID NO:1 known to block ICAM-1, exerts both an acute and durable response because it also inhibits the activation of TLR-9.
- The primary sequence of SEQ ID NO:1 does not predict its action as a TLR-9 antagonist.
- The specific primary sequence of SEQ ID NO:1 suggests possible secondary structures that could influence TLR-9 activity, but does not predict the most stable or optimal structures.
- Conditions that influence the secondary structure of SEQ ID NO:1 also influence its activity as a TLR-9 antagonist.
- It has been discovered that an oligonucleotide, with the primary sequence of SEQ ID NO:1, when submitted to conditions that optimize its secondary structure, is a more potent treatment agent for mucosal inflammation than predicted by the primary sequence alone.
- TLRs are a key means by which the host recognizes and mounts an immune response to foreign molecules. They also provide a mechanism by which the innate and adaptive immune responses are linked. Specifically, TLR-9 recognizes bacterial and viral DNA through certain unmethylated CpG motifs not present in mammalian DNA. Cells contained within the mucosa can therefore “sense” and respond to the presence of “foreign” DNA. Binding of such ligands activates the immune system to further respond to and remove the pathogen.
- It is also known that synthetic oligonucleotides (ODN) containing CpG dinucleotide sequences can stimulate immune responses through the TLR-9 pathway. In addition, the use of synthetic oligonucleotides has shown utility as inhibitors of inflammatory cytokines and these actions are known to be mediated though inhibitory actions on TLR-9.
- The published literature documenting the properties of DNA oligonucleotides required for binding to TLR-9 is extensive and has focused on both agonist and antagonist sequences. While the CpG motif is known to be required for stimulatory activity, there are no canonical sequences known to absolutely predict antagonist sequences. Certain inhibitors have been described previously in the art. In addition to these triplet-containing inhibitory ODNs, several groups have reported other specific DNA sequences that could inhibit TLR-9 mediated activation by CpG containing ODNs. These “inhibitory” or “suppressive” motifs are rich in poly “G” (e.g., “GGG”) or “GC” sequences, tend to be methylated and are present in the DNA of mammals and certain viruses. Other inhibitory sequences have been identified as containing a “GGGG” motif within the sequences. Certain repetitive TTAGGG elements, present at high frequency in mammalian telomeres, have been observed to down-regulate CpG-induced immune activation demonstrate that synthetic oligonucleotides containing the TTAGGG element mimic this activity and could be effective in the prevention/treatment of certain Th1-dependent autoimmune diseases.
- The secondary structure of ODNs has also been studied as a basis for defining the DNA structure necessary for binding to TLR-9. However, there does not appear to be a secondary structure that absolutely specifies binding affinity, although sequence specific effects on structure are observed to alter the ODN agonist or antagonist activity.
- The surprising finding is that SEQ ID NO:1 is an antagonist of TLR-9 and is devoid of agonist activity. Further, the invention defines specific conditions that contribute to the predicted secondary structure of SEQ ID NO:1 and relate the secondary structure to TLR-9 antagonism.
- The following figures are part of the application, where;
-
FIG. 1 is a dose response graph for SEQ ID NO:1 stimulation of TLR-9. -
FIG. 2 is a dose response of TLR-9 inhibition by SEQ ID NO:1. -
FIG. 3 is a graph showing SEQ ID NO:1 inhibition curves for ICAM-1 and TLR-9. -
FIG. 4 is a thermodynamic predication of duplex stability for SEQ ID NO:1 and ODN2006 hetero duplex vs SEQ ID NO:1 homo duplex. -
FIG. 5 is a graph showing the inhibition of TLR-9 activated by E. coli genomic DNA. -
FIG. 6 shows: Upper—CD spectra of SEQ ID NO:1 in ddH20 at 4° C. Lower—spectra 20-95° C. -
FIG. 7a shows a 190 nm peak intensity as a function of temperature. -
FIG. 7b shows a 220 nm peak intensity as a function of temperature. -
FIG. 8 shows the spectra of SEQ ID NO:1 in 5 mM spermine. -
FIG. 9 shows a schematic of the experimental set up. -
FIG. 10 shows IC50's for SEQ ID NO:1 inhibition of ODN2006 activation of TLR-9. -
FIG. 11 shows the Corneal Fluorescein Staining (CFS) evaluation of alicaforsen (1 mM and 10 mM dose) in scopolamine dry eye mouse model atday 6 andday 10. Each circle represents one eye and the line is the mean of the group. Two-way and one-way ANOVA Analyses were performed followed by Dunnett's Tests for multiple comparisons * p<0.05; ** p<0.001. -
FIG. 12 shows the evaluation of alicaforsen in Ovalbumin-Induced Murine Model of Allergic Asthma. One-way ANOVA followed by Dunnett's multiple comparison test compared to vehicle control; *p<0.05; ** p<0.01. Student's unpaired, two-tailed T-test comparing 1 mM alicaforsen to vehicle control; #p<0.05. - The present invention provides the following examples which are not limiting.
- SEQ ID NO:1 was screened for dose response activity to determine possible EC50 for TLR9 activation at seven different doses (0.01, 0.05, 0.1, 0.5, 1, 5 and 10 μM) in triplicate. Briefly, the TLR9/NF-kB luciferase reporter HEK 293 cell line (Abeomics, San Diego, Calif.) was plated in 96-well white solid plates at 5×104 cells per well for 16 h. Cells were treated with different doses of SEQ ID NO:1 as well as with 20 ug/ml of CpG ODN-2006, a known agonist of TLR-9 in triplicate for 16 h. Luciferase activity was then measured and analyzed.
- As shown in
FIG. 1 , SEQ ID NO:1 was devoid of agonist activity up to concentrations as high as 100 uM while a 1.0 uM dose of ODN2006 produced a 7.5-fold increase in TLR-9 induced gene activation. - SEQ ID NO:1 was next screened for dose responsive inhibition activity to determine the IC50 against TLR9-mediated NF-kB induction at seven different doses (0.1, 1, 5, 10, 25, 50 and 100 μM) in triplicate. Briefly, the TLR9/NF-kB luciferase reporter HEK 293 cell line was plated in 96-well white solid plates at 5×104 cells per well for 16 h. Cells were pretreated with different doses of SEQ ID NO:1 in triplicate for 1 h. Cells were then treated with 20 ug/ml of CpG ODN2006 to activate TLR9. After 16 h, luciferase activity was measured and analyzed. These results are shown in
FIG. 2 . - The activity of SEQ ID NO:1 as an antagonist of TLR-9 requires higher concentrations than the inhibition of ICAM-1 expression. The comparative dose responses are shown in
FIG. 3 , in relation to the dose used in the enema formulation. - It is evident from the data of
FIG. 3 that the therapeutic dose of SEQ ID NO:1 used for the treatment of IBD (659 uM) is sufficient to provide therapeutic levels of the drug for both mechanisms of action. - It was also necessary to rule out a direct inhibitory effect of SEQ ID NO:1 on the binding of the activator ODN2006. A screen of the two structures using the Oligo Analyzer 3.1 program (Integrated DNA Technologies, Inc.) showed that alicaforsen was energetically more likely to form a dimer with itself than with ODN2006. This comparison is shown in
FIG. 4 . - While the data of
FIG. 4 indicate that SEQ ID NO:1 is more likely to form a homodimer than a heterodimer with ODN2006, additional experiments tested the antagonist activity of SEQ ID NO:1 in the presence of E. coli genomic DNA as the activator. In this assay, SEQ ID NO:1 remained antagonistic to the activation of TLR-9 (FIG. 5 ). - The homodimer shown in
FIG. 4 is the most energetically favorable duplex structure for SEQ ID NO:1. Of interest was whether this secondary structure may influence the TLR-9 inhibitory activity and under which conditions the duplex was most stable - The predicted duplex structure is stabilized by 4 Watson-Crick type bonds flanked by G-A mismatches and another 2 G-C pairs. The CpG motifs remain unconstrained on the non-overlapping 3′ ends for each duplex member.
- SEQ ID NO:1 was therefore subjected to Circular Dichroism (CD) spectroscopy to gather information about the possible secondary structure. CD of DNA can be utilized to detect all 3 major forms of duplex structure (B, A and Z) and is sensitive to conditions that disrupt the structure such a heating. Of interest was the stability of any secondary structure detected at or above physiologic temperatures. Shown in
FIG. 6 is the CD spectra of sample SEQ ID NO:1 in ddH20 at 4C. The profile shows features characteristic of duplexes in the B-form of DNA, namely a characteristic low intensity positive band at ˜280 nm, two low intensity negative bands at ˜210 nm and ˜255 nm and an positive intense band at ˜190 nm - The positive band at 190 nm was found to be sensitive to temperature between 4° C. and 20° C. Further heating to 80° C. showed a loss of >85% of the signal strength. This background signal was achieved at 40° C. making it unlikely that the structure is stable to physiological temperature under these conditions.
- Additional thermal denaturation of the putative duplex was also studied in the presence of Na+ at concentrations of 50 mM and 150 mM. Sodium fluoride was used as Cl− ions interfere with the CD spectra in this UV region.
- As can be seen in
FIG. 7(a) , the intensity of the 190 nm peak is more stable to heating under both 50 and 150 mM sodium conditions, retaining at least 50% of its structure to 40° C. In addition, the intensity of the 190 nm peak returned to pre-heated levels once the samples were cooled back to 20° C. This implies that the observed secondary structure is reversible after melting. - No significant changes in the negative peak at 210 nm were detected upon heating. However, the positive peak at 220 nm was found to respond similarly to that of the 190 nm peak. These data are shown in
FIG. 7(b) . - Additional experiments were conducted to test the influence of Mg++ and polyamines on the stability of the structure. Surprisingly, the polyamine, spermine at 5 mM in the presence of 50 mM Na+ completely abolished the secondary structure (
FIG. 8 ). - This could be a function of the altered phosphate backbone of SEQ ID NO:1 which contains 20 sulfur substitutions in place of O— on each phosphate group (phosphorothioate).
- To test the effect of treatments known to stabilize and/or destabilize the secondary structure of SEQ ID NO:1 a series of experiments explored the effect of heat, Na+, Mg+ and spermine on the TLR-9 antagonist activity of SEQ ID NO:1. The samples and conditions of these tests are diagramed in
FIG. 9 . - Briefly, samples of SEQ ID NO:1 were dissolved in Tris buffer at pH 7.2 including 50 mM NaCl, in the presence of either 15 mM Mg++ or 5 mM spermine or both Mg++ and spermine. One sample remained at room temperature while the remaining samples were heated to 90° C. for 3 min and then allowed to cool to room temperature. The samples were then diluted to the indicated concentrations and incubated with the target cells for 1 hr, prior to the addition of 1.0 uM ODN2006 to stimulate TLR-9. The results of the experiment are shown in
FIG. 10 . - It can be seen in
FIG. 10 that conditions which were observed to alter the secondary structure of SEQ ID NO:1 also influence its activity as an inhibitor of TLR-9. It is also noted that these conditions were maintained during the heating and cooling step where they had an opportunity to influence the secondary structure of SEQ ID NO:1. However, once diluted into the cell culture media, the conditions would be altered to those of the media and the temperature would revert to 37° C. The differences seen are therefore stable under normal physiological conditions. - This alteration of conditions, when the samples are incubated with cells, may be the reason that some activity is still observed in the spermine-treated samples, even though the CD spectra would indicate that the pre-incubation conditions removed the secondary structure of the duplex. Alternatively, the results seen with spermine could represent remaining TLR-9 inhibitory activity of non-duplexed molecules (monomers).
- To test the effect of SEQ ID NO:1 on the condition inflammation of the eye, the effect of two different concentrations of alicaforsen in a murine model of dry eye by scopolamine administration was investigated.
- In a model of mice, the application of transdermal scopolamine patches to the mid-tail is used to reduce aqueous tear production and thus mimic lacrimal gland insufficiency. The function of scopolamine is to induce a pharmacologic blockade of cholinergic receptors in the lacrimal gland and therefore to decrease aqueous production. The desiccation is amplified by adding environmental stress. Animals are exposed to a low-humidity environment and constant airflow.
-
-
- Species: Mouse.
- Strain: C57BL/6N (pigmented).
- Age: Approximately 6-7 weeks (at the first day of induction).
- Number/sex: 55 females (
study 40; reserve 15).
- Throughout the study, animals had free access to food and water. They were fed with a standard dry pellet diet. Tap water was available ad libitum from plastic bottles.
- 40 animals were included in this study. Animals were selected based on good health and homogeneous body weight. Only healthy animals without visible ocular defect (corneal opacity) were involved in this study. Animals were randomized into the study groups using a macro function in Excel® software on the basis of the mean of the corneal fluorescein staining scores from both eyes on
Day 3. - Dry eye symptoms were induced in pigmented C57BL/6N mice by exposing them to a controlled environment room (approximate relative humidity <25%, temperature 22° C.±2° C.), in a cage with an air-flow around 15 L/min and transdermal scopolamine administration (0.5 mg/72 h) for eleven days.
- Mice were treated with transdermal scopolamine administration (0.5 mg/72 h; Scopoderm TTS®). The transdermal scopolamine patch was wrapped near the tail base of the mouse, secured with cellophane tape. Patches were reapplied every 48 hours.
- Mice were randomized into 4 groups of 10 animals. The study was divided into 2 experimental sets with 5 animals of each group represented. All mice were treated on day one and then treated for 10 days in total according to the following regime:
-
- Optimmune® group: two doses per day on
Days Day 4 toDay 9. - alicaforsen (10 mM and 1 mM) group: one dose per day.
- Vehicle Group: one dose per day.
- Optimmune® group: two doses per day on
- All test items, control items and comparator item were instilled in both eyes (5 μL per administration), using a micropipette.
- Tear production and corneal defects were assessed at baseline, on
Days - Body Weights
- The body weight of all animals was recorded.
- General Appearance
- Each day, the general clinical signs and the appearance of all animals was observed.
- Ocular Examinations
- Two types of ocular examinations were conducted:
- A) Measurement of aqueous tear production PRT test.
-
- Tear production was measured with the PRT test (Zone-Quick, FCI-Ophthalmics) on both eyes, before administration on
Day 3 and at least one hour after the second treatment for the other days of the study. The thread was placed in the lateral cantus of the lateral conjunctival fornix for 30 seconds. The thread wet by tears would turn red, indicated aqueous tear production. This data was expressed in millimetres.
- Tear production was measured with the PRT test (Zone-Quick, FCI-Ophthalmics) on both eyes, before administration on
- B) Corneal fluorescein staining (CFS)
-
- At the different time points the measurement was performed before administration on
Day 3 and at least one hour after the second treatment for the other days of the study. The eyes of the animals from all groups were examined by slit-lamp observation using blue light after 0.5% fluorescein eye drop instillation (0.5 μL). Punctuate staining was recorded with the standardized National Eye Institute (NEI) grading system giving a 0-3 score to each of the 5 areas in which the corneas were divided.
- At the different time points the measurement was performed before administration on
- A slight loss in body weight was observed for the majority of animals of all groups between
Day 0 andDay 10 due to dry eye conditions. - alicaforsen (10 mM and 1 mM), Vehicle, and Optimmune® did not affect the behaviour of the animals.
- On
Day 3, the tear production decreased for all groups. The values of untreated group were stable untilDay 10. These data showed a good induction of dry eye in this murine model. - Results from the CFS are summarized in Table 1 below and in
FIG. 11 : -
TABLE 1 Dry eye symptoms evaluation Corneal fluorescein staining score (mean ± SD) Treatment Day 6 Day 10ALICAFORSEN 10.8 ± 2.0 9.7 ± 2.2 (10 mM) ALICAFORSEN 10.5 ± 2.6 9.3 ± 3.1 (p = 0.0429) (1 mM) Vehicle (PBS) 10.5 ± 2.3 11.3 ± 2.4 Optimmune ® 8.0 ± 2.3 (p = 0.0021) 8.5 ± 2.3 (p = 0.0020) Note: Statistical analysis relative to Vehicle group with Dunn's multiple comparison tests: p < 0.05. - The Vehicle group had dry eye symptoms from
Day 3 toDay 10, showing that this study is validated. - The group treated with Optimmune® showed corneal fluorescein staining scores lower than the Vehicle group on Day 6 (p=0.0021) and Day 10 (p=0.0020).
- The groups treated with alicaforsen (1 mM and 10 mM) had similar corneal fluorescein staining scores to Vehicle group on
Day 6. - The groups treated with alicaforsen (1 mM and 10 mM) showed corneal fluorescein staining scores lower than the Vehicle group on
Day 10 and the group treated with alicaforsen (1 mM) showed a significant difference (p=0.0429) compared to vehicle. Under these experimental conditions, multiple topical administrations of alicaforsen (1 mM and 10 mM) were clinically well tolerated. - The Vehicle group had dry eye symptoms from
Day 3 toDay 10, showing that this study is validated. - Optimmune® 0.2% and alicaforsen (1 mM) groups showed a statistically significant reduction in the dry eye symptoms as measured by corneal fluorescein staining
- To test the effect of alicaforsen on conditions such as asthma, an ovalbumin (OVA)-induced allergic asthma mouse model was treated with alicaforsen.
- Allergic asthma was modeled in female BALB/c mice by initial sensitization to OVA followed by subsequent intranasal challenge of purified OVA.
- Mice were monitored throughout the study for changes in body weight and general signs of sickness. Allergic response to OVA was measured by examining bronchoalveolar lavage fluid (BALF) for inflammatory cell influx and the presence of the inflammatory cytokine IL-13.
- Additionally, animals in experimental groups were treated via intranasal (IN) administration of either alicaforsen, at 1 mM dosing concentration, control vehicle (PBS), or intraperitoneal (IP) dexamethasone as a positive anti-inflammatory control.
- Table 2 and 3 below detail the test items and test materials used during the study.
-
TABLE 2 Cat. Lot Storage Exp. Material Name No. No. Manufacturer Condition Date Positive Dexamethasone NDC P355990 APP 18-22° C. April Control 63323-165-05 Pharmaceuticals 2018 Sensitization/ OVA, endotoxin- LS003059 55P16242 Worthington 2-8° C. December Challenge free 2017 -
TABLE 3 Cat. Lot. Storage Exp. Material Name No. No. Manufacturer Condition Date Positive Dexamethasone NDC 63323-165-05 P355990 APP 18-22° C. April Control Pharmaceuticals 2018 Senaitization/ OVA, endotoxin- LS003059 55P16242 Worthington 2-8° C. December Challenge free 2017 Aluminum Vac-alu-250 5295 Invivogen 18-22° C. May Hydroxide gel 2018 PBS 10010031 RN13F2486 Life RT February Technologies 2018 Anesthesia Isofluorane NDC 66794-013-25 B57D16A Piramal 18-22° C. March Item Healthcare 2021 Multiplex kit Mouse MCYTOMAG-70K 2990274 Millipore 2-8° C. July Cytokine/Chemokine 2018 magnetic Bead panel - Dosing of alicaforsen at a concentration of 1 mM was prepared based on a 0.878 drug content factor and MW of 6795.9 g/mol. Prepared solutions were stored at 2-8° C. for the duration of the study.
- 1 mL dexamethasone stock solution (4 mg/mL) was added to 3 mL saline for a solution concentration of 1 mg/mL.
- Chicken egg OVAlbumin (OVA) was dissolved in PBS to a concentration of 1 mg/mL. 1 mg/mL OVA solution was diluted 1:1 in Alum adjuvant and stored at 2-8° C. overnight until use. Final dosing concentration was 100 μg OVA per 200 μL OVA/alum mixture.
- 1 mL sterile PBS was added to 10 mg OVA for a solution concentration of 10 mg/mL.
- 0.35 mL OVA stock solution was added to 1.75 ml PBS for a solution concentration of 1.67 mg/mL. Final dosing concentration=50 μg OVA in 30 μL.
-
-
Species/Strain: Balb/c Gender: Female Total # of 55 Animals: Age: 7-8 weeks of age at study initiation. Body Weight: Weight variation of the animals at study initiation did not exceed ±20% of the mean weight. Animals Health: The health status of the animals used in this study was examined on arrival. All animals were in good health, were acclimatized to laboratory conditions, and were used in the study. Acclimation: At least 72 hours. Housing: During acclimation and study, animals were housed within a limited access rodent facility and kept in groups of maximum 5 mice. Mice were housed insterilized individually ventilated polysulfone cages with irradiated cob bedding material. Food and Water: Animals were provided ad libitum a commercial rodent diet and free access to drinking water, supplied to each cage via sterilised polyethylene bottles. All food and water is sterilised. Environment: Automatically controlled environmental conditions were set to maintain temperature at 20-26° C. with relative humidity (RH) of 30-70%, a 12:12 hour light:dark cycle. Randomisation: Animals were randomly assigned to cages on arrival. Animals were assigned to treatment groups on day −1. Termination: Euthanasia anesthesia overdose. - The table 4 below lists the experimental group(s) used in the study.
-
TABLE 4 Group Group Group Disease TI/vehicle TI/vehicle TI/vehicle TI/vehicle Number Size Description Induction Route Dose Level Volume Dosage Dosing Regime 1 N = 5 Naive N/A N/A N/A N/A N/A 2 N = 10 Disease Only Sensitization which NA NA NA NA 3 N = 10 Vehicle OVA/Alum via ip IN NA 30 μl Once daily on 4 N = 10 Dexamethasone injection on day 0IP 10 mg/ kg 10 ml/ kg study days 14, 5 N = 10 Alicaforsca and 14, and IN 1 mM 30 μl 25-27. challenged with OVAin PBS intranasal on days 14, 25-27 - Disease Induction (Groups 2-6):
- On
days - On
days 14 and 25-27, each animal was administered an intranasal challenge of 30 μL PBS containing 50 μg OVA. - Treatment with Test Item:
- alicaforsen was administered at 1 mM concentration intra-nasally (IN) in a volume of 30 μL. Treatments were performed on the same days as OVA challenge on
Study Days 14 and 25-27 (4 total treatments). Treatments were administered 1 hour following OVA challenge. - 10 mg/kg dexamethasone was administered in 200 μL volume/animal (intraperitoneal) on
Study Days 14 and 25-27 (4 total treatments). - Careful examinations were carried out daily. Observations for changes in skin, fur, eyes, mucus membranes, occurrence of secretions and excretions and autonomic activity were included. Significant changes in gait, posture, and response to handling, or the presence of bizarre behavior, tremors, convulsions, sleep and coma were recorded.
- Body weight of animals was determined shortly before the study commencement and twice weekly thereafter.
- Termination, Tissue Sampling and Subsequent Analyses:
- On
Day 28, all mice were euthanised via detamine+xylazine overdose and exsanguination. - Bonchoalveolar lavage was performed on euthanised animals. Briefly, an angiocatheter was placed into trachea. 1 mL of PBS was instilled into the lungs and allowed to flow back out into the syringe; the PBS was then instilled and removed again. The resultant Bronchoalveolar lavage fluid (BALF) was centrifuged at 500×g for 5 mins.
- The non-cellular portion of the BALF was stored at −80° C. The levels of IL-13 were analyzed by Luminex technology.
- The cellular portion of the BALF was used to analyze the cell influx. The total number of leukocytes within the BALF and different cell types present were examined via flow cytometry.
- Granulocytes: CD45+; Non-autofluorescent; Gr-1+
Eosinophils: CD45+; Non-autofluorescent; Gr-1+; Siglec F+ - Animals sensitized and challenged with OVA protein showed signs of disease at experiment termination, including significantly increased alveolar influx of total leukocytes, granulocytes and eosinophils when compared to naïve mice. Furthermore, diseased animals showed significantly increased levels of IL-13 in BALF.
- Treatment with the positive control dexamethasone significantly reduced granulocyte and eosinophil populations and IL-13 levels in the BALF, indicating a reduction in the allergic response to OVA.
- Intranasal administration of alicaforsen (1 mM) resulted in significantly lower levels of total leukocytes (CD45+ cells) in the BALF and significantly reduced the proportion of eosinophils. There was also a significant reduction in total granulocyte frequency in 1 mM alicaforsen treated group compared to the vehicle group. Additionally, treatment with 1 mM alicaforsen led to significantly lower IL-13 levels in the BALF. These data indicated a reduction in allergic response to OVA.
- The results are shown in
FIG. 12 and in Table 5 below, the results demonstrate the anti-inflammatory effect of alicaforsen on a murine model of allergic asthma. -
TABLE 5 Flow analysis of BALF mean, standard error of the mean (SEM) and IL-13 expression in BALF mean (SEM). Granulocyte Eosinophil (Frequency of CD45+) (Frequency of CD45+) Mean SEM Mean SEM Group 1: Naive 37.14** 8.17 5.16** 2.36 Group 2: Disease 84.23 0.92 76.23 1.63 only Group 3: Vehicle 86.69 1.22 81.97 1.69 Group 4: 51.88** 8.53 46.60** 8.70 Dexamethasone Group 5: 80.16# 2.56 56.64**## 8.02 alicaforsen 1 mMTotal CD45 BALF cells in BALF IL-13 pg/ml Mean SEM Mean SEM Group 1: Naive 20186** 1095 8.0** 0.0 Group 2: Disease 413776 57945 53.8 11.8 only Group 3: Vehicle 521708 51727 27.5 5.5 Group 4: 236574 63225 13.2** 2.3 Dexamethasone Group 5: 217303**## 26340 13.4*# 2.6 alicaforsen 1 mM
Claims (12)
1. A pharmaceutical composition comprising SEQ ID NO:1 with a cation, optionally selected from the following list Na+, K+, Mg++, Ca++, Ba++, Mn++, Ni++, Li++, Zn++, and Cr+++, preferably Na+, more preferably 40-200 mM Na+, optionally including 2-20 mM Mg2+.
2. A composition as claimed in claim 1 , wherein the Na+ is 100-190 mM, more preferably 140-160 mM.
3. A composition as claimed in any one of claims 1 to 2 , which also comprises one or more of hydroxymethyl cellulose, methyl paraben sodium, propylparaben sodium, monobasic sodium phosphate monohydrate, sodium hydroxide, hydrochloric acid and/or water.
4. A composition as claimed in any one of claims 1 to 3 wherein the composition is in the form of a liquid syrup, gel, film, cream, powder, tablet and/or enema.
5. A composition as claimed in any one of claims 1 to 4 , wherein the components are in the following ranges
6. A composition as claimed in any one of claims 1 to 5 for use in medicine.
7. A composition, as claimed in claim 6 , wherein the use is for the prevention or treatment of inflammatory bowel disease, rectal stump, radiation-induced proctitis, pouchitis, asthma, inflammation of the eye, dry eye, rhinitis, sinusitis or graft versus host disease.
8. Use of SEQ ID NO:1 in the manufacture of a medicament as claimed in any one of claims 1 to 6 for the prevention or treatment of inflammatory bowel disease, rectal stump, radiation-induced proctitis, pouchitis, asthma, inflammation of the eye, dry eye, graft versus host disease, rhinitis or sinusitis.
9. A method of treating inflammatory bowel disease, rectal stump, radiation-induced proctitis, pouchitis, asthma, inflammation of the eye, dry eye, rhinitis or sinusitis, or grant-versus host disease, the method comprising administration of a composition as claimed in any one of claims 1 to 5 to a patient in need thereof.
10. A method of making a composition as claimed in any one of claims 1 to 5 , the method comprising combining SEQ ID NO:1 with a cation, optionally selected from the following list Na+, K+, Mg++, Ca++, Ba++, Mn++, Ni++, Li++, Zn++, and Cr++, preferably Na+, more preferably 40-200 mM Na+, optionally including 2-20 mM Mg2+.
11. A composition, as claimed in any one of claims 1 to 6 , wherein the composition is in the form of an enema and wherein the composition is formulated in a dosage form to provide a concentration of SEQ ID NO:1 at 2 mg/ml per day.
12. A composition, as claimed in any one of claims 1 to 6 , wherein the composition is in the form of an enema and wherein the composition is formulated in a dosage form to provide a concentration of SEQ ID NO:1 at 1-4 mg/ml per day
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/570,051 US20220119819A1 (en) | 2017-01-06 | 2022-01-06 | Formulation |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1700257.7 | 2017-01-06 | ||
GBGB1700257.7A GB201700257D0 (en) | 2017-01-06 | 2017-01-06 | New formulation |
PCT/EP2018/050336 WO2018127582A2 (en) | 2017-01-06 | 2018-01-08 | New formulation |
US201916476221A | 2019-07-05 | 2019-07-05 | |
US17/570,051 US20220119819A1 (en) | 2017-01-06 | 2022-01-06 | Formulation |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2018/050336 Continuation WO2018127582A2 (en) | 2017-01-06 | 2018-01-08 | New formulation |
US16/476,221 Continuation US11220690B2 (en) | 2017-01-06 | 2018-01-08 | Formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220119819A1 true US20220119819A1 (en) | 2022-04-21 |
Family
ID=58463770
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/476,221 Active US11220690B2 (en) | 2017-01-06 | 2018-01-08 | Formulation |
US17/570,051 Abandoned US20220119819A1 (en) | 2017-01-06 | 2022-01-06 | Formulation |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/476,221 Active US11220690B2 (en) | 2017-01-06 | 2018-01-08 | Formulation |
Country Status (7)
Country | Link |
---|---|
US (2) | US11220690B2 (en) |
EP (2) | EP3565571B1 (en) |
JP (2) | JP7267922B2 (en) |
CA (1) | CA3049479A1 (en) |
ES (1) | ES2920052T3 (en) |
GB (1) | GB201700257D0 (en) |
WO (1) | WO2018127582A2 (en) |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040033977A1 (en) | 1990-08-14 | 2004-02-19 | Bennett C. Frank | Oligonucleotide modulation of cell adhesion |
US6096722A (en) * | 1990-08-14 | 2000-08-01 | Isis Pharmaceuticals Inc. | Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases |
US5576302A (en) | 1991-10-15 | 1996-11-19 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity |
AU7559894A (en) | 1993-08-05 | 1995-02-28 | Isis Pharmaceuticals, Inc. | Oligomers for modulating metabolic function |
US7235653B2 (en) | 1996-12-31 | 2007-06-26 | Isis Pharmaceuticals, Inc. | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
WO1999001579A1 (en) * | 1997-07-01 | 1999-01-14 | Isis Pharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
EP1080103A4 (en) * | 1998-05-21 | 2003-07-02 | Isis Pharmaceuticals Inc | Compositions and methods for non-parenteral delivery of oligonucleotides |
EP1115858B1 (en) | 1998-09-25 | 2003-04-02 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Antisense-sequences for inhibiting the expression of the adhesion molecule icam-1 |
US7960355B2 (en) * | 2003-05-23 | 2011-06-14 | Isis Pharmaceuticals, Inc. | Compositions and methods for the modulation of the expression of B7 protein |
CN102060806A (en) | 2003-09-11 | 2011-05-18 | iTherX药品公司 | Cytokine inhibitors |
CA2554424A1 (en) | 2004-01-26 | 2005-08-11 | Control Delivery Systems, Inc. | Controlled and sustained delivery of nucleic acid-based therapeutic agents |
US8168600B2 (en) * | 2004-04-23 | 2012-05-01 | Isis Pharmaceuticals, Inc. | Compositions and methods for topical delivery of oligonucleotides |
KR20070089980A (en) | 2004-12-02 | 2007-09-04 | 아이시스 파마수티컬즈 인코포레이티드 | Therapeutic antisense oligonucleotide composition for the treatment of inflammatory bowel disease |
ES2390499T3 (en) * | 2006-06-12 | 2012-11-13 | Opko Pharmaceuticals, Llc | Compositions and methods for inhibition of angiogenesis by sirna |
JP2012521765A (en) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | RNA interference-mediated inhibition of intracellular adhesion molecule 1 (ICAM-1) gene expression using small interfering nucleic acids (siNA) |
DE102010007562A1 (en) * | 2010-02-10 | 2011-08-11 | sterna biologicals GmbH & Co KG, 35043 | Dermatological, pharmaceutical composition suitable for oligonucleotides |
WO2013123996A1 (en) | 2012-02-24 | 2013-08-29 | Astrazeneca Uk Limited | Novel sirna inhibitors of human icam-1 |
JP2017514908A (en) | 2014-05-01 | 2017-06-08 | アールエックスアイ ファーマシューティカルズ コーポレーション | Methods for the treatment of disorders in the front of the eye utilizing nucleic acid molecules |
GB201407822D0 (en) * | 2014-05-02 | 2014-06-18 | Atlantic Pharmaceuticals Holdings Ltd | Use of a composition |
-
2017
- 2017-01-06 GB GBGB1700257.7A patent/GB201700257D0/en not_active Ceased
-
2018
- 2018-01-08 ES ES18702408T patent/ES2920052T3/en active Active
- 2018-01-08 EP EP18702408.8A patent/EP3565571B1/en active Active
- 2018-01-08 WO PCT/EP2018/050336 patent/WO2018127582A2/en unknown
- 2018-01-08 CA CA3049479A patent/CA3049479A1/en active Pending
- 2018-01-08 US US16/476,221 patent/US11220690B2/en active Active
- 2018-01-08 EP EP22156721.7A patent/EP4052720A3/en not_active Withdrawn
- 2018-01-08 JP JP2019537123A patent/JP7267922B2/en active Active
-
2022
- 2022-01-06 US US17/570,051 patent/US20220119819A1/en not_active Abandoned
-
2023
- 2023-04-20 JP JP2023069687A patent/JP2023093639A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11220690B2 (en) | 2022-01-11 |
EP4052720A3 (en) | 2022-11-09 |
JP2023093639A (en) | 2023-07-04 |
WO2018127582A2 (en) | 2018-07-12 |
WO2018127582A3 (en) | 2018-08-09 |
EP3565571A2 (en) | 2019-11-13 |
GB201700257D0 (en) | 2017-02-22 |
EP3565571B1 (en) | 2022-03-23 |
JP7267922B2 (en) | 2023-05-02 |
EP4052720A2 (en) | 2022-09-07 |
ES2920052T3 (en) | 2022-08-01 |
CA3049479A1 (en) | 2018-07-12 |
US20190367927A1 (en) | 2019-12-05 |
JP2020504145A (en) | 2020-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5875191B2 (en) | New compositions for treating CMT and related disorders | |
US20240100081A1 (en) | Compositions and methods for treating age-related macular degeneration and geographic atrophy | |
JP6742362B2 (en) | SiRNAs for treating and/or preventing ocular conditions and their use in methods and compositions | |
JP5749651B2 (en) | Compounds and methods for reducing mobilization and / or migration of polymorphonuclear cells | |
Royer et al. | Complement and CD4+ T cells drive context-specific corneal sensory neuropathy | |
JP2015523346A (en) | Treatment method of neutropenia using retinoid agonist | |
US20220119819A1 (en) | Formulation | |
US20190388459A1 (en) | New therapeutic uses | |
Sekar et al. | Impairing Gasdermin D-mediated pyroptosis is protective against retinal degeneration | |
Liang et al. | miR-328-3p Affects Axial Length Via Multiple Routes and Anti-miR-328-3p Possesses a Potential to Control Myopia Progression | |
ES2750125T3 (en) | SiRNA and its use in methods and compositions for the treatment and / or prevention of eye conditions | |
CN106456571B (en) | Composition for treating mechanical neuronal injury | |
Cervantes et al. | RIPK3 facilitates host and pathogen interactions after oral Toxoplasma gondii infection | |
Zhang et al. | Selective microRNA expression of exosomes from retinal pigment epithelial cells by oxidative stress | |
JP2018513862A (en) | Specific trifluoroethylquinoline analogs for use in the treatment of Sjogren's syndrome | |
Vereertbrugghen et al. | CD4+ T cells drive corneal nerve damage but are dispensable for corneal epitheliopathy development in dry eye disease | |
ALRASHDI | CONTRIBUTION OF THE VOLTAGE-GATED SODIUM CHANNEL NAV1. 6 AND TOLL LIKE RECEPTOR 2 IN THE PATHOPHYSIOLOGY OF EAE | |
Cervantes | An exploration of host responses to oral and chronic Toxoplasma gondii infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ATLANTIC PHARMACEUTICALS (HOLDINGS) LTD, GREAT BRITAIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WILSON WATERWORTH, TOBY;JOHNSON, LORIN K.;THOMAS, JANETTE;AND OTHERS;SIGNING DATES FROM 20190716 TO 20190724;REEL/FRAME:058582/0174 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |